lung cancer
Conditions
Interventions
None listed
Sponsors
Juntendo University School of Medicine, Pulmonary Critical Care Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.stage IIIB or IV patients with recurrent or advanced non-small cell lung cancer who are administered carboplatin and paclitaxel in the presence or absence of bevacizumab as 1st line chemotherapy. 2.Neurotoxity is occured within a week after chemotherapy, VAS scale in neurotoxicity including pain and paresthesia>or=40mm.The neurotoxity is screened for questionnaire which is used in Japanese patients with chronic pain. 3.Age>or=20 years 4.Patients who agreed to participate in the study, and signed informed consent form
Exclusion criteria
Exclusion criteria: 1.Patients with renal dysfunction,Ccr<or =30ml/min 2.The patients taking the following drugs recommended by IASP Antidepressant/SSRI/SNRI/Antiepileptic agent/Opioid 3.Patients having the intracranial lesion with clinical symptoms 4.Patients with neuropathic pain by direct invasion of a tumor 5.Patient having the peripheral neuropathy caused by the etiology other than chemotherapy,VAS prior to the start of chemotherapy>or=30mm 6.Patients with past history of hypersensitivity to any of the ingredients in pregabalin 7.Patients with impaired consciousness 8.Patients with cardiac dysfunction 9.Other patients considered to be ineligible by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in VAS scale in neurotoxicity including pain and paresthesia before and 14 days after pregabalin administration. | — |
Countries
Japan
Contacts
Public ContactRyo Koyama
Juntendo University School of Medicine Pulmonary Critical Care Medicine
Outcome results
None listed